$DVAX
DYNAVAX TECHNOLOGIES CORP

2018 Form 10-K Financial Statement

#000156459019004888 Filed on February 27, 2019

View on sec.gov

Income Statement

Concept 2018 2017 Q4 2017 Q3
Revenue $8.198M $21.00K $53.00K
YoY Change 2407.03% -99.71% -67.28%
Cost Of Revenue $21.80M
YoY Change
Gross Profit -$13.60M
YoY Change
Gross Profit Margin -165.89%
Selling, General & Admin $64.77M $8.540M $5.310M
YoY Change 136.67% 14.63% -52.63%
% of Gross Profit
Research & Development $74.95M $17.41M $16.42M
YoY Change 15.33% -5.59% -29.32%
% of Gross Profit
Depreciation & Amortization $14.48M $1.970M $790.0K
YoY Change 226.86% 185.51% 27.42%
% of Gross Profit
Operating Expenses $161.5M $27.15M $22.44M
YoY Change 67.67% 4.87% -35.87%
Operating Profit -$175.1M -$22.39M
YoY Change 82.4% -35.73%
Interest Expense $9.338M $530.0K $430.0K
YoY Change 1161.89% 278.57% 152.94%
% of Operating Profit
Other Income/Expense, Net -$70.00K -$110.0K -$170.0K
YoY Change -85.6% -95.7% 466.67%
Pretax Income -$154.6M -$27.42M -$22.13M
YoY Change 61.22% 26.13% -36.21%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$158.9M -$27.42M -$22.13M
YoY Change 66.99% 26.13% -36.22%
Net Earnings / Revenue -1938.27% -130576.19% -41750.94%
Basic Earnings Per Share -$2.55
Diluted Earnings Per Share -$2.55 -$448.8K -$383.9K
COMMON SHARES
Basic Shares Outstanding 62.36M
Diluted Shares Outstanding 62.36M

Balance Sheet

Concept 2018 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $145.5M $191.9M $191.7M
YoY Change -24.18% 135.69% 74.91%
Cash & Equivalents $49.30M $26.58M $20.72M
Short-Term Investments $96.20M $165.3M $171.6M
Other Short-Term Assets $6.100M $5.000M $4.600M
YoY Change 22.0% -26.47% -19.3%
Inventory $19.00M $312.0K
Prepaid Expenses
Receivables $3.700M $900.0K $800.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $174.4M $198.0M $197.1M
YoY Change -11.92% 121.01% 67.74%
LONG-TERM ASSETS
Property, Plant & Equipment $17.10M $16.62M $16.60M
YoY Change 3.01% -3.23% -11.23%
Goodwill $2.244M
YoY Change 13.85%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.600M $1.270M $1.900M
YoY Change 194.74% 280.24% 111.11%
Total Long-Term Assets $36.50M $20.76M $20.70M
YoY Change 75.48% 3.39% -5.05%
TOTAL ASSETS
Total Short-Term Assets $174.4M $198.0M $197.1M
Total Long-Term Assets $36.50M $20.76M $20.70M
Total Assets $210.9M $218.8M $217.8M
YoY Change -3.61% 99.48% 56.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.300M $4.539M $2.200M
YoY Change 17.78% 19.57% -42.11%
Accrued Expenses $25.80M $9.695M $10.60M
YoY Change 82.98% -13.38% -60.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.00M $18.59M $12.90M
YoY Change 104.3% -7.04% -57.7%
LONG-TERM LIABILITIES
Long-Term Debt $100.9M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.900M $643.0K $500.0K
YoY Change 1383.33% 45.15% 0.0%
Total Long-Term Liabilities $109.8M $643.0K $500.0K
YoY Change 18200.0% 45.15% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.00M $18.59M $12.90M
Total Long-Term Liabilities $109.8M $643.0K $500.0K
Total Liabilities $147.8M $19.24M $13.40M
YoY Change 669.79% -6.07% -56.77%
SHAREHOLDERS EQUITY
Retained Earnings -$907.3M
YoY Change 11.72%
Common Stock $1.108B
YoY Change 22.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.10M $199.5M $204.4M
YoY Change
Total Liabilities & Shareholders Equity $210.9M $218.8M $217.8M
YoY Change -3.61% 99.48% 56.35%

Cashflow Statement

Concept 2018 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$158.9M -$27.42M -$22.13M
YoY Change 66.99% 26.13% -36.22%
Depreciation, Depletion And Amortization $14.48M $1.970M $790.0K
YoY Change 226.86% 185.51% 27.42%
Cash From Operating Activities -$131.3M -$17.75M -$17.13M
YoY Change 69.38% -32.46% -39.28%
INVESTING ACTIVITIES
Capital Expenditures $4.187M -$300.0K -$130.0K
YoY Change 525.86% -75.81% -91.88%
Acquisitions
YoY Change
Other Investing Activities $70.65M $6.360M -$82.22M
YoY Change -165.4% -78.35% -398.11%
Cash From Investing Activities $55.47M $6.060M -$82.35M
YoY Change -151.03% -78.45% -416.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 99.07M 18.08M 81.71M
YoY Change -47.26% -8318.18% 20851.28%
NET CHANGE
Cash From Operating Activities -131.3M -17.75M -17.13M
Cash From Investing Activities 55.47M 6.060M -82.35M
Cash From Financing Activities 99.07M 18.08M 81.71M
Net Change In Cash 22.75M 6.390M -17.77M
YoY Change 879.93% 294.44% 865.76%
FREE CASH FLOW
Cash From Operating Activities -$131.3M -$17.75M -$17.13M
Capital Expenditures $4.187M -$300.0K -$130.0K
Free Cash Flow -$135.5M -$17.45M -$17.00M
YoY Change 73.29% -30.31% -36.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63996911
CY2018Q2 dei Entity Public Float
EntityPublicFloat
760000000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49348000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26584000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
96188000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
165270000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12111000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
312000
CY2018Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
9714000
CY2017Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4359000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16041000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9695000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7000000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38033000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18593000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
100871000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
643000
CY2018Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3704000
CY2017Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
854000
CY2018Q4 us-gaap Inventory Net
InventoryNet
19022000
CY2017Q4 us-gaap Inventory Net
InventoryNet
312000
CY2017Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
1306000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6102000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3697000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
174364000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
198023000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17064000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16619000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11717000
CY2018Q4 us-gaap Goodwill
Goodwill
2144000
CY2017Q4 us-gaap Goodwill
Goodwill
2244000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
619000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
629000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4976000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1270000
CY2018Q4 us-gaap Assets
Assets
210884000
CY2017Q4 us-gaap Assets
Assets
218785000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5278000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4539000
CY2017Q4 us-gaap Liabilities
Liabilities
19236000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
62000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1107693000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-881000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-907325000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
199549000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
218785000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8915000
CY2018Q4 us-gaap Liabilities
Liabilities
147819000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8198000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
327000
CY2016 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11043000
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
64770000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27367000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37257000
CY2017 us-gaap Restructuring Charges
RestructuringCharges
2783000
CY2018 us-gaap Operating Expenses
OperatingExpenses
161517000
CY2017 us-gaap Operating Expenses
OperatingExpenses
96332000
CY2016 us-gaap Operating Expenses
OperatingExpenses
121750000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1146000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1134000
CY2016 dvax Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value
IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue
-83000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14728000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
89201000
CY2017 dvax Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value
IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue
1613000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
293000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
185936000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14917000
CY2018 dvax Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value
IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue
-523000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
594000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23478000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3621000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3244000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2257000
CY2016 dvax Write Off Of Assets In Progress
WriteOffOfAssetsInProgress
862000
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-98000
CY2016 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-259000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22754000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2322000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20530000
CY2017 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-488000
CY2016 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-52000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18710000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
312000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2405000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1830000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-560000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
10000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-91000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1559000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
193000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-178000
CY2017 dvax Reversal Of Deferred Rent Upon Lease Amendment
ReversalOfDeferredRentUponLeaseAmendment
209000
CY2016 dvax Cash Settled Portion Of Stock Based Compensation Expense
CashSettledPortionOfStockBasedCompensationExpense
602000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
23478000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
14917000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
14126000
CY2018 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
10862000
CY2017 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
1194000
CY2018 dvax Non Cash Interest Expense
NonCashInterestExpense
2755000
CY2018 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
2850000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3706000
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
936000
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
103000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3417000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1915000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1181000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12597000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3198000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-11759000
CY2016 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2654000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-131301000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-77518000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-107051000
CY2018 dvax Payments To Acquire Technology Licenses
PaymentsToAcquireTechnologyLicenses
11000000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
213804000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
227672000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
126754000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
284457000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
119638000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
220760000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4187000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
669000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7757000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
55466000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108703000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
86249000
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
99000000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
185936000
CY2018 dvax Tax Withholdings Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
TaxWithholdingsProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
-523000
CY2017 dvax Tax Withholdings Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
TaxWithholdingsProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
1613000
CY2016 dvax Tax Withholdings Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
TaxWithholdingsProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
-84000
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
594000
CY2017 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
293000
CY2016 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
615000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
99071000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
187842000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
531000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-482000
CY2017 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
701000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
602000
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
145604000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
191934000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45421000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49967000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27213000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24891000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
6583000
CY2016 dvax Accrual For Litigation Settlement And Insurance Recovery
AccrualForLitigationSettlementAndInsuranceRecovery
4975000
CY2017 dvax Release Of Accrual For Litigation Settlement And Insurance Recovery
ReleaseOfAccrualForLitigationSettlementAndInsuranceRecovery
4975000
CY2018 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
199000
CY2017 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
86000
CY2016 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
2354000
CY2018 dvax Noncash Or Part Noncash Acquisition Of Technology License
NoncashOrPartNoncashAcquisitionOfTechnologyLicense
12773000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
96256000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
96188000
CY2017Q4 dvax Accrued Third Party Research Expenses Current
AccruedThirdPartyResearchExpensesCurrent
3567000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
96188000
CY2018 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2017 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2016 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2018 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2017 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2016 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2018 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2017 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2016 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management&#8217;s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results could differ materially from these estimates.</p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any losses on our cash equivalents and marketable securities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts as described further below. We estimate our allowance for doubtful accounts based on<font style="font-size:12pt;"> </font>an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have not recorded any allowance for doubtful accounts.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates will require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2018, 2017 and 2016, 83%, 90% and 92%, respectively, of our revenues were earned in the United States. As of December 31, 2018 and 2017, 24% and 15%, respectively, of our long-lived assets were located in the United States and the remaining long-lived assets were located in Germany.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into distribution agreements with a limited number of wholesalers and specialty distributors in the U.S. All of our product revenue are to these customers. For the year ended and at December 31, 2018, respectively, our three largest customers represented approximately 68% of our product revenue and 71% of our trade receivable balance.</p>
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Equity Level2 To Level1 Transfers Amount
FairValueEquityLevel2ToLevel1TransfersAmount
0
CY2017Q4 us-gaap Fair Value Equity Level2 To Level1 Transfers Amount
FairValueEquityLevel2ToLevel1TransfersAmount
0
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24289000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
80000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
145536000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
191854000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
96256000
CY2018Q4 dvax Accrued Third Party Development Expenses Current
AccruedThirdPartyDevelopmentExpensesCurrent
1377000
CY2018Q4 dvax Accrued Revenue Reserves Liability Current
AccruedRevenueReservesLiabilityCurrent
1033000
CY2018Q4 dvax Accrued Third Party Research Expenses Current
AccruedThirdPartyResearchExpensesCurrent
7819000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6562000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
349000
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19773000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2500000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8056000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1194000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11717000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1306000
CY2018 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P16M
CY2018 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2018Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
12029000
CY2017Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
12104000
CY2018Q4 dvax Laboratory Equipment Gross
LaboratoryEquipmentGross
6938000
CY2017Q4 dvax Laboratory Equipment Gross
LaboratoryEquipmentGross
6686000
CY2018Q4 dvax Computer Equipment Gross
ComputerEquipmentGross
5465000
CY2017Q4 dvax Computer Equipment Gross
ComputerEquipmentGross
4760000
CY2018Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1809000
CY2017Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1629000
CY2018Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
11367000
CY2017Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
10873000
CY2018Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
2605000
CY2017Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
1176000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
40213000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37228000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23149000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20609000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8058000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6180000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
151000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
346000
CY2017Q4 dvax Accrued Third Party Development Expenses Current
AccruedThirdPartyDevelopmentExpensesCurrent
522000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7317000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3439000
CY2018Q4 dvax Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
25755000
CY2017Q4 dvax Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
14054000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
4000000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2400000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2200000
CY2018Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
2300000
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
600000
CY2018Q1 dvax Amount Available For Borrowing Under Long Term Debt Agreement
AmountAvailableForBorrowingUnderLongTermDebtAgreement
175000000
CY2018Q1 dvax Secured Long Term Debt Noncurrent Plus Interest In Kind
SecuredLongTermDebtNoncurrentPlusInterestInKind
101800000
CY2018Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-12-31
CY2018 us-gaap Loss Contingency Settlement Agreement Date
LossContingencySettlementAgreementDate
September 7, 2016
CY2017Q4 us-gaap Loss Contingency Accrual Payments
LossContingencyAccrualPayments
900000
CY2018Q4 dvax Product Revenue Allowance And Remaining Reserves Classified As Accrued Liabilities
ProductRevenueAllowanceAndRemainingReservesClassifiedAsAccruedLiabilities
1000000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
42000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5750000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-109165000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
36751000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
86943000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5534000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2975000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.56
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.30
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.80
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.20
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
18.28
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.90
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y5M19D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y5M8D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M13D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
651000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
644000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
466000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
900000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
8100000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
13000000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12100000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23478000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14917000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14126000
CY2018 dvax Cash Settled Portion Of Stock Based Compensation Expense
CashSettledPortionOfStockBasedCompensationExpense
0
CY2017 dvax Cash Settled Portion Of Stock Based Compensation Expense
CashSettledPortionOfStockBasedCompensationExpense
0
CY2018Q2 us-gaap Employee Stock Ownership Plan Esop Shares In Esop
EmployeeStockOwnershipPlanESOPSharesInESOP
600000
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2016 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2017Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-114484000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
2040000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-112444000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-38183000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-334000
CY2017 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1960000
CY2016 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1950000
CY2017 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
3823000
CY2016 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
3016000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41830000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
274000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-108800000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1229000
CY2018 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
165000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1254000
CY2017 dvax Income Tax Reconciliation Net Operating Loss And Tax Credit Limitation
IncomeTaxReconciliationNetOperatingLossAndTaxCreditLimitation
56962000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
53000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
231000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
700000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
178730000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
146300000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
34064000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
29658000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
10137000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
6551000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
943000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1422000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1147000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
731000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
225021000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
184662000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
224746000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
184388000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
275000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
274000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
275000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
274000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
275000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1461000
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5318000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-38958000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62346000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62650000
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62694000
CY2017Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
105000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-20318000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-22128000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-27421000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60

Files In Submission

Name View Source Status
0001564590-19-004888-index-headers.html Edgar Link pending
0001564590-19-004888-index.html Edgar Link pending
0001564590-19-004888.txt Edgar Link pending
0001564590-19-004888-xbrl.zip Edgar Link pending
dvax-10k_20181231.htm Edgar Link pending
dvax-20181231.xml Edgar Link completed
dvax-20181231.xsd Edgar Link pending
dvax-20181231_cal.xml Edgar Link unprocessable
dvax-20181231_def.xml Edgar Link unprocessable
dvax-20181231_lab.xml Edgar Link unprocessable
dvax-20181231_pre.xml Edgar Link unprocessable
dvax-ex211_13.htm Edgar Link pending
dvax-ex231_15.htm Edgar Link pending
dvax-ex311_17.htm Edgar Link pending
dvax-ex312_14.htm Edgar Link pending
dvax-ex321_9.htm Edgar Link pending
dvax-ex322_12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending